Bould Opportunities PLC Stock price

Equities

PSL

GB00B1TK2453

Construction Supplies & Fixtures

Delayed London S.E. 02:30:01 2019-10-07 am EDT 5-day change 1st Jan Change
0.023 GBX -.--% Intraday chart for Bould Opportunities PLC +24.32% +43.75%
Sales 2019 - Sales 2020 - Capitalization 5.71K 7.19K
Net income 2019 - 0 Net income 2020 - 0 EV / Sales 2019 -
Net cash position 2019 378K 477K Net cash position 2020 84K 106K EV / Sales 2020 -
P/E ratio 2019
-0.01 x
P/E ratio 2020
-0.02 x
Employees -
Yield 2019 *
-
Yield 2020
-
Free-Float 65.34%
More Fundamentals * Assessed data
Dynamic Chart
Bould Opportunities plc Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Cizzle Biotechnology Limited completed the acquisition of Bould Opportunities PLC from Antos Glogowski and others in a reverse merger transaction. CI
Bould Opportunities PLC Announces Board Changes CI
Cizzle Biotechnology Limited agreed to acquire Bould Opportunities PLC from Antos Glogowski and others for £21 million in a reverse merger transaction. CI
Antos Glogowski cancelled the acquisition of PhotonStar Technology Ltd. from Bould Opportunities PLC. CI
Photonstar Led Group plc Reports Earnings Results for the Half Year Ended June 30, 2019 CI
Bould Opportunities PLC Announces Change of Registered Office CI
Bould Opportunities plc Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Bould Opportunities PLC Announces Board Changes CI
Antos Glogowski offered to acquire PhotonStar Technology Ltd. from Bould Opportunities PLC for £1. CI
PhotonStar To Seek Acquisitions CI
Photonstar Led Group plc Announces the Change of Registered Office Address CI
PhotonStar LED Group PLC Announces Management Changes CI
Paul Macleur and other members of the management team of Camtronics Vale Limited cancelled the acquisition of Camtronics Vale Limited from PhotonStar LED Group PLC in a management buyout transaction. CI
PhotonStar LED Group Plc Announces Resignation of Majd Zoorob as Director CI
More news
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer company engaged in developing a blood test for the early detection of the different forms of lung cancer. The Company's proof-of-concept prototype test is based on the ability to detect a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. It helps to reduce the need for repeated computed tomography (CT) scanning. The Company provides its product AZD1656 is treatment for COVID19 patients. AZD1656 is an immunomodulator which damps down the inflammatory response characteristic of coronavirus disease (COVID-19) infection, while enhancing the part of the immune response. The Company has developed a prototype confirmative test to address the false positive rates of CT scanning to avoid unnecessary invasive testing.
More about the company
  1. Stock
  2. Equities
  3. Stock Bould Opportunities PLC - London S.E.